First Berlin Equity Research has published a correction of the research update on Marinomed Biotech AG (ISIN: ATMARINOMED6) published on 24/09/2026. Analyst Alexander Rihane has ended his coverage of the stock.

Abstract
After not receiving anticipated milestone payments from Unither Pharmaceuticals, Marinomed filed for court-administered restructuring on 22 July. Today, the insolvency administrator Dr. Ulla Reisch filed a motion to close the business. The motion was accepted, and the insolvency court ordered the closure of Marinomed’s operations. Dr. Ulla Reisch will now initiate a sale of the company’s assets. We end our coverage of Marinomed Biotech AG.